Immunic to Participate in Scientific and Investor Conferences in February
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, announced its participation in several key scientific and investor conferences throughout February 2023. On February 2, Darius-Jean Namdjou will join a panel on EU and UK pharmacovigilance regulations in London. A webcast on celiac disease research featuring experts will be held on February 9. CEO Daniel Vitt will present a company overview at the SVB Securities Global Biopharma Conference on February 16. Additionally, Robert J. Fox will present data on the phase 2 EMPhASIS trial at the ACTRIMS Forum in San Diego from February 23-25. More details and registration links are available on Immunic's website.
- None.
- None.
February 1-2 : 31st Pharmacovigilance 2023. Darius-Jean Namdjou, Ph.D., Head of Regulatory Affairs & Pharmacovigilance atImmunic , will participate as a panelist in a roundtable discussion entitled, "Regulatory - EU andUK Regulations & Guidelines in Pharmacovigilance" at this conference inLondon onThursday, February 2, 2023 , at4:00 pm GMT .February 9 :Immunic's Celiac Disease R&D Webcast.Immunic's management will be joined by renowned key opinion leaders to discuss today's treatment options and the unmet medical need for celiac disease, in a webcast onFebruary 9, 2023 , at11:00 am ET . Featured key opinion leaders will be:Joseph A. Murray , M.D., Professor of Medicine, Director,Celiac Disease Research , John andShirley Berry Professor of Gastrointestinal Sciences,Division of Gastroenterology and Hepatology ,Department of Internal Medicine , Mayo Clinic,Rochester, MN Michael Schumann , M.D., Attending Physician in Internal Medicine and Gastroenterology,Department of Gastroenterology, Infectious Diseases and Rheumatology , CampusBenjamin Franklin , Charité – UniversitätsmedizinBerlin
The celiac disease R&D webcast will be held virtually via Zoom. To participate, please register in advance at: https://imux.zoom.us/webinar/register/WN_wI-01YeJSbe4XRTFO1PLQw. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access. An archived replay of the webcast will be available on the "Events and Presentations" section of
February 13-16 :SVB Securities Global Biopharma Conference .Daniel Vitt , Ph.D., Chief Executive Officer and President ofImmunic , will present a company overview at this virtual conference onThursday, February 16, 2023 , at1:40 pm ET . A live webcast of the presentation will be available on the "Events and Presentations" section ofImmunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.February 23-25 :ACTRIMS Forum 2023.Robert J. Fox , M.D., Staff Neurologist,Mellen Center for Multiple Sclerosis , Vice-Chair for Research,Neurologic Institute ,Cleveland Clinic ,Cleveland, Ohio will present data from the blinded and open-label extension parts of the company's phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838), a selective oral DHODH inhibitor, at this conference inSan Diego, California . The poster presentation will be accessible on the "Events and Presentations" section ofImmunic's website at: ir.imux.com/events-and-presentations.- Abstract Number: 697
- Poster Title: Assessment of effect of vidofludimus calcium on MS progression in the blinded treatment and open-label extension periods of the phase 2 study (EMPhASIS) in relapsing-remitting multiple sclerosis
- Poster Number: P068
- Poster Session: Poster Session 1
- Date:
Thursday, February 23, 2023 - Time: 6:30 –
7:30 pm PT
Members of
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and investor conferences.
Contact Information
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-and-investor-conferences-in-february-301729634.html
SOURCE
FAQ
What conferences will Immunic participate in February 2023?
Who will represent Immunic at the Pharmacovigilance 2023 Conference?
What will be discussed during Immunic's Celiac Disease R&D Webcast?
When will Immunic present at the SVB Securities Global Biopharma Conference?